PH12021551140A1 - Methods of treating follicular lymphoma - Google Patents

Methods of treating follicular lymphoma

Info

Publication number
PH12021551140A1
PH12021551140A1 PH12021551140A PH12021551140A PH12021551140A1 PH 12021551140 A1 PH12021551140 A1 PH 12021551140A1 PH 12021551140 A PH12021551140 A PH 12021551140A PH 12021551140 A PH12021551140 A PH 12021551140A PH 12021551140 A1 PH12021551140 A1 PH 12021551140A1
Authority
PH
Philippines
Prior art keywords
follicular lymphoma
methods
treating follicular
treating
lymphoma
Prior art date
Application number
PH12021551140A
Other languages
English (en)
Inventor
Sriram Balasubramanian
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PH12021551140A1 publication Critical patent/PH12021551140A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PH12021551140A 2018-11-30 2021-05-19 Methods of treating follicular lymphoma PH12021551140A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773678P 2018-11-30 2018-11-30
PCT/US2019/063234 WO2020112761A1 (en) 2018-11-30 2019-11-26 Methods of treating follicular lymphoma

Publications (1)

Publication Number Publication Date
PH12021551140A1 true PH12021551140A1 (en) 2021-10-25

Family

ID=68966021

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021551140A PH12021551140A1 (en) 2018-11-30 2021-05-19 Methods of treating follicular lymphoma

Country Status (16)

Country Link
US (1) US20200171034A1 (https=)
EP (1) EP3886992A1 (https=)
JP (1) JP2022513666A (https=)
KR (1) KR20210097160A (https=)
CN (1) CN113164782A (https=)
AU (1) AU2019388899A1 (https=)
BR (1) BR112021009978A2 (https=)
CA (1) CA3120960A1 (https=)
EA (1) EA202191509A1 (https=)
IL (1) IL283365A (https=)
JO (1) JOP20210126A1 (https=)
MA (1) MA54292A (https=)
MX (1) MX2021006368A (https=)
PH (1) PH12021551140A1 (https=)
SG (1) SG11202105309YA (https=)
WO (1) WO2020112761A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
CA2914284A1 (en) * 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20160032404A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
CA2980393A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
HK1250925A1 (zh) * 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor
PH12021551936A1 (en) * 2019-02-15 2022-05-23 Janssen Biotech Inc Combination therapy for treatment of b-cell malignancies

Also Published As

Publication number Publication date
CN113164782A (zh) 2021-07-23
JOP20210126A1 (ar) 2019-11-26
SG11202105309YA (en) 2021-06-29
KR20210097160A (ko) 2021-08-06
EP3886992A1 (en) 2021-10-06
US20200171034A1 (en) 2020-06-04
JP2022513666A (ja) 2022-02-09
EA202191509A1 (ru) 2021-10-26
BR112021009978A2 (pt) 2021-08-17
WO2020112761A1 (en) 2020-06-04
MA54292A (fr) 2021-10-06
AU2019388899A1 (en) 2021-06-10
IL283365A (en) 2021-07-29
MX2021006368A (es) 2021-10-13
CA3120960A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
MX2019008197A (es) Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos.
MX2021005646A (es) Métodos de tratamiento de cáncer con agentes de unión a tubulina.
EP3689910A3 (en) Method of using anti-cd79b immunoconjugates
NZ736853A (en) Methods of treating cancer patients with farnesyl transferase inhibitors
MA39836A (fr) Combinaison de lénalidomide et d'une construction de polypeptide, et ses utilisations
MX381582B (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
NZ628320A (en) Treatment of psoriatic arthritis using apremilast
MX2017003797A (es) Macrociclos peptidomimeticos y usos de los mismos.
MX2018008652A (es) Hisopo de muestreo oral y usos de este.
SG11202105380RA (en) Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
MY190411A (en) Improved uricase sequences and methods of treatment
MX2020011817A (es) Metodos para tratar el linfoma.
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MX394796B (es) Terapia combinada para el tratamiento de neoplasias malignas.
EP4484443A3 (en) Materials and methods for treatment of friedreich ataxia and other related disorders
MX2022002699A (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2019005450A (es) Composiciones y metodos farmaceuticos.
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
MY200803A (en) Mpo inhibitors for use in medicine
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
PH12021551140A1 (en) Methods of treating follicular lymphoma